ResApp Fundamentals & General Discussion, page-8

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 8 Last

Share
Profile

Follow
pilko3

6,822 Posts.

868

06/08/20

20:10

Post #: 46359460
Share

Originally posted by eason2946: ↑

Hi all,

Given discussion with FDA is still unknown at this stage, I believe FDA approval is not gonna be on the horizon until some time in 2021 unfortunately. Personally I think the MOU with RB is the next big thing for ResApp that's really gonna change its fundamental and it's currently under the radar. Obviously any new European telehealth partners will boost the SP as well.

After some research, I found this interesting article:

https://hbw.pharmaintelligence.informa.com/RS149075/Reckitt-Invests-In-AI-Symptom-Checker-To-Unlock-SelfCare

It seems like RB has invested in self-care digital health sector and Your.Md is their first step. I imagine their partnership with ResAppDx is a similar strategic MOU and developing an app like Your.Md where consumers can use it to identify different respiratory conditions and provide recommendednext steps. I believe this direct to consumer approach has the largest market size and the most effect market penetration and the revenue stream will be much bigger than telehealth. We should hopefully hear an update about this by the end of the year.

Below is the info from ResApp's investor presentation back in April this year:

What's everyone thought on this?

GLTAH and DYOR.

Expand

RAP stitch up most Android devices and RB buys out RAP for USD $3.15 IMHO. Don't say no when we surmise just imagine it becoming reality

RAP Price at posting: 14.5¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

GTR

GTI extends uranium mineralisation at Lo Hema through development drilling

CU6

Clarity progresses SECuRE trial with positive safety results

3 stocks with antimony news on Thursday

CHN

Chalice jumps on Putin nickel export ban threat – but then there's bad news

DXB

Dimerix begins recruiting young kidney disease patients in Mexico for Phase 3